Oncology has had a run of regulatory news this autumn. The FDA approved Tecentriq for adjuvant stage III dMMR colon cancer on October 91. The EU's CHMP backed an alternative Libtayo dosing schedule on October 162. Moderna and Merck plan to present detailed intismeran results at ESMO on October 243. For an investor, the most instructive case is the one with a hard date and no product revenue yet: Summit Therapeutics, whose ivonescimab Biologics License Application has an FDA goal date of November 14, 20264.
What Summit's filings say
Summit reported zero revenue in both FY2023 and FY20245. Its losses are large and growing. Net income was -$614.9 million in FY2023, -$221.3 million in FY2024 and -$1,079.6 million in FY20255. The FY2025 loss is just over $1.08 billion, nearly five times the prior year's. Loss per share was -$0.99, -$0.31 and -$1.44 across the same three years5.
Cash burn is the figure to watch. Operating cash flow went from -$76.8 million in FY2023 to -$142.1 million in FY2024 and -$322.9 million in FY20255. That is more than double the prior year's outflow. The net loss and the cash outflow are very different sizes, most obviously in FY2023 (-$614.9 million against -$76.8 million). The verified data does not say why, so we do not guess. Readers should look at the cash-flow statement, not the headline loss alone, to see what the company is spending.
Capital spending on equipment and facilities is tiny: $128,000 in FY2023, $139,000 in FY2024 and $657,000 in FY20255. The money is going on running trials and the company, not on building factories. R&D expense is verified only for FY2023, at $59.5 million5, so we cannot show its trend.
The cash balance has moved sharply
Cash at quarter-ends has swung widely5:
- $71.4 million at FY2023 year-end
- $104.9 million at FY2024 year-end
- $297.9 million at Q2 2025
- $238.6 million at Q3 2025
- $225.3 million at FY2025 year-end
- $106.5 million at Q1 2026
- $419.4 million at Q2 2026
Between Q1 and Q2 2026, cash rose by nearly four times. The verified data records the balances but not where the money came from. A rise of that size in a company with no revenue and large outflows points to money raised from outside, but that is our inference, not a checked fact. The filings, not this article, are where to confirm it.
The pattern is the point. Cash climbed in 2025, drained to $106.5 million by Q1 2026 and was then replenished. At the FY2025 operating outflow of $322.9 million, the Q1 2026 balance would not have lasted a full year. That is simple arithmetic on checked figures, not a forecast of what Summit will do. For a pre-revenue biotech, an FDA decision on the lead asset tends to be tied closely to the next financing.
The dealmaking around it
Our narrative record describes capital consolidating around oncology services and combinations. It cites McKesson and CD&R's acquisition of Option Care Health and a collaboration among Summit, AstraZeneca and Daiichi Sankyo on ivonescimab plus Datroway in first-line triple-negative breast cancer6. Our dossier contains no price, terms or financial figures for either deal. We therefore cannot say what they are worth, and we will not estimate. Our entity graph confirms only that Option Care Health is headquartered in Bannockburn, IL, and that AstraZeneca competes with Eli Lilly6.
Elsewhere in oncology, Novocure reported quarterly net revenues of $184 million, up 16% year over year, with 18% global active patient growth7. Its CEO Frank Leonard called it "our strongest quarter to date, with record net revenues and active patients on therapy"7. It is a useful contrast with Summit: a company with revenue and growing patient numbers, against one funded by its balance sheet until a drug is approved. Gilead's Trodelvy plus Keytruda received a positive CHMP opinion in first-line PD-(L)1-positive triple-negative breast cancer on July 24, 20268. Kyowa Kirin's final MINT study of mogamulizumab in 109 patients reported a 62.4% best overall response rate9.
The AI layer: mostly forecast
The AI strand of this story comes from AstraZeneca's Puja Sapra, in an MIT Technology Review piece10. She describes a "lab of the future" where "AI [makes] predictions, robotic systems [execute] experiments, and instruments [generate] data"10. She argues that "Data is our differentiator"10. She also concedes that "One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body"10. That admission matters most for investors: safety prediction is where costly late-stage failures happen, and the piece offers no results showing it solved.
Treat this section with caution. Of the 11 claims we checked from that source, none held up under our measured reliability test10. That does not mean Sapra was wrong. It means the claims are opinion and forecast that our checks could not confirm. Nothing in the dossier shows an AI-designed molecule contributing to any of the approvals or filings above. The Summit, Tecentriq, Libtayo and Trodelvy news comes from conventional clinical programmes.
Wire-service press releases, such as those from NewsEOD, held up better but not perfectly. Across 4,960 claims checked, 56% held up7. Company announcements of results are a starting point, not a verified conclusion.
What to watch
- November 14: the FDA goal date for ivonescimab4. The outcome will shape how Summit funds itself next.
- October 24: detailed intismeran data at ESMO, and any regulatory discussions Moderna and Merck report3.
- Summit's next quarterly filing: whether the cash balance holds near the Q2 2026 level of $419.4 million, given an operating outflow that ran at $322.9 million for FY20255.
- Deal terms: any disclosed figures for the Option Care Health and ivonescimab collaboration deals. Until then, they are headlines without numbers.
Sources:
1 Via News event record, "FDA approves Tecentriq for adjuvant stage III dMMR colon cancer" (October 09, 2026)
2 Via News event record, "CHMP positive opinion on updated Libtayo dosing regimen" (October 16, 2026)
3 Via News event record, "Detailed intismeran results to be presented at ESMO" (October 24, 2026)
4 Via News event record, "FDA PDUFA Goal Date Set for Ivonescimab BLA" (November 14, 2026)
5 Via News verified data, Summit Therapeutics Inc.: capex, cash, EPS, net income, operating cash flow, operating income, R&D expense, revenue; SEC filing (FY2023 to Q2 2026)
6 Via News narrative and entity graph, "Oncology Dealmaking and Regulatory Momentum Meet AI-Driven Drug Discovery"
7 NewsEOD, "Novocure Reports Second Quarter 2026 Financial Results" (2026-07-23)
8 NewsEOD, "CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer" (2026-07-24)
9 NewsEOD, "Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome" (2026-10-12)
10 MIT Technology Review, "How AI helps scientists design the next generation of medicines" (undated)
